Show simple item record

dc.contributor.authorvan Zyl, Gert Uves
dc.contributor.authorvan Mens, Thijs E
dc.contributor.authorMcIlleron, Helen
dc.contributor.authorZeier, Michele
dc.contributor.authorNachega, Jean B
dc.contributor.authorDecloedt, Eric
dc.contributor.authorMalavazzi, Carolina
dc.contributor.authorSmith, Peter
dc.contributor.authorHuang, Yong
dc.contributor.authorvan der Merwe, Lize
dc.contributor.authorGandhi, Monica
dc.contributor.authorMaartens, Gary
dc.date.accessioned2011-08-31T20:40:26Z
dc.date.available2011-08-31T20:40:26Z
dc.date.issued2011-04
dc.identifier.citationLow lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. 2011, 56 (4):333-9 J. Acquir. Immune Defic. Syndr.en
dc.identifier.issn1944-7884
dc.identifier.pmid21239995
dc.identifier.doi10.1097/QAI.0b013e31820dc0cc
dc.identifier.urihttp://hdl.handle.net/10144/141404
dc.description.abstractIn resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic failure.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en
dc.subject.meshAdulten
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshCase-Control Studiesen
dc.subject.meshCross-Sectional Studiesen
dc.subject.meshDrug Resistance, Viralen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHairen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPlasmaen
dc.subject.meshPyrimidinonesen
dc.subject.meshRNA, Viralen
dc.subject.meshSouth Africaen
dc.subject.meshTreatment Failureen
dc.subject.meshViral Loaden
dc.titleLow lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.en
dc.contributor.departmentDivision of Medical Virology, Department of Pathology, NHLS Tygerberg and Stellenbosch University, Tygerberg, South Africa. guvz@sun.ac.zaen
dc.identifier.journalJournal of Acquired Immune Deficiency Syndromes (1999)en
refterms.dateFOA2019-03-04T08:47:39Z
html.description.abstractIn resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic failure.


Files in this item

Thumbnail
Name:
van Zyl J Acqu Imm Def Syn Low ...
Size:
205.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record